|
Market Closed -
OTC Markets
09:58:20 2021-10-14 EDT
|
5-day change | 1st Jan Change | ||
| 435.44 USD | +27.70% |
|
+13.62% | -0.20% |
| 07-29 | Virbac, without the alibi |  |
| 07-21 | Virbac: Impressive execution in Q2; we smell a guidance upgrade in Q3 |  |
Main competitors
| P/E (N) | Price to Book (N) | PEG (N) | EV / Sales (N) | EV / EBITDA (N) | EV / EBIT (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | 13.15x | 9.23x | -1.93x | 4.06x | 9.43x | 10.84x | 2.9% | 30.49B | |
| 171.52x | 1.8x | -1.33x | 2.9x | 14.63x | 16.76x | -.--% | 11.83B | |
| 14.24x | 1.11x | 0.41x | 1.09x | 4.03x | 9.65x | 3.45% | 3.77B | |
| 16.32x | 2.18x | 1.24x | 1.88x | 9.24x | 11.47x | 0.52% | 3.23B | |
| 60.65x | 2.7x | 0.41x | - | - | - | 0.59% | 2.19B | |
| 35.27x | 2.26x | 0.68x | 3.98x | 14.26x | 20.77x | -.--% | 1.97B | |
| 13.88x | 3.69x | 0.13x | 1.3x | 7.71x | 9.13x | 1.39% | 1.39B | |
| 20.05x | 1.8x | 2.25x | 2.47x | 11.85x | 18.18x | 1.56% | 1.3B | |
| 32.9x | 1.15x | 1.71x | - | - | - | 0.46% | 996M | |
| 14.49x | 1.25x | -15.15x | 1.05x | 5.1x | 7.28x | 1.39% | 954M | |
| 12.92x | 1.38x | 1.06x | - | - | - | - | 898M | |
| 21.57x | 2.33x | -1.72x | - | - | - | 0.94% | 729M | |
| 20.72x | 1.38x | -2.8x | - | - | - | - | 525M | |
| 22.79x | 0.49x | 0.14x | 1.72x | 8.35x | 17.94x | 2.07% | 360M | |
| Average | 33.61x | 2.34x | -1.06x | 2.27x | 9.40x | 13.56x | 1.27% | 4.33B | |
| Weighted average by Cap. | 47.45x | 5.57x | -1.29x | 3.30x | 10.27x | 12.53x | 1.89% |
- Stock Market
- Stocks
- VIRP Stock
- VRBCF Stock
- Sector Virbac
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
